Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 1;66(1):74-9.
doi: 10.1097/QAI.0000000000000108.

Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia

Praphan Phanuphak  1 , Sunee Sirivichayakul, Awachana Jiamsakul, Somnuek Sungkanuparph, Nagalingeswaran Kumarasamy, Man Po Lee, Thira Sirisanthana, Pacharee Kantipong, Christopher Lee, Adeeba Kamarulzaman, Mahiran Mustafa, Rossana Ditangco, Tuti Merati, Winai Ratanasuwan, Thida Singtoroj, Rami Kantor
Affiliations

Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia

Praphan Phanuphak et al. J Acquir Immune Defic Syndr. .

Abstract

Background: We compared treatment outcomes of transmitted drug resistance (TDR) in patients on fully or partially sensitive drug regimens.

Methods: Factors associated with survival and failure were analyzed using Cox proportional hazards and discrete time conditional logistic models.

Results: TDR, found in 60 (4.1%) of 1471 Asian treatment-naive patients, was one of the significant predictors of failure. Patients with TDR to >1 drug in their regimen were >3 times as likely to fail compared to no TDR.

Conclusions: TDR was associated with failure in the context of non-fully sensitive regimens. Efforts are needed to incorporate resistance testing into national treatment programs.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None

References

    1. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394. - PubMed
    1. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197:867–870. - PubMed
    1. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12:307–317. - PubMed
    1. Hingankar NK, Thorat SR, Deshpande A, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis. 2012;54(Suppl 4):S348–354. - PMC - PubMed
    1. Sirivichayakul S, Phanuphak P, Pankam T, et al. HIV drug resistance transmission threshold survey in Bangkok, Thailand. AntivirTher. 2008;13(Suppl 2):109–113. - PubMed

Publication types

Substances